Anti-Inflammatory Therapy Shows Promise in Treatment of Depression
Anti-inflammatory drugs similar to those used to treat conditions such as rheumatoid arthritis and psoriasis could in future be used to treat some cases of
Anti-inflammatory drugs similar to those used to treat conditions such as rheumatoid arthritis and psoriasis could in future be used to treat some cases of
The Merck KGaA/Pfizer co-developed immune checkpoint inhibitor Avelumab will be assessed in combination with Vaccinex’s VX15/2503 through a clinical collaboration whose value was not disclosed.
The Merck KGaA/Pfizer co-developed immune checkpoint inhibitor Avelumab will be assessed in combination with Vaccinex’s VX15/2503 through a clinical collaboration whose value was not disclosed.
Recent advances in understanding different RNAs and unique features of their biology have revealed a wealth of information. However, approaches to identify small molecules that
Scientists from Fred Hutchinson Cancer Research reported data from an early-phase study of patients with advanced non-Hodgkin’s lymphoma (NHL) who received JCAR014, a chimeric antigen
Over the years vitamin C supplementation has had a tumultuous relationship with empirical science. In 1753, James Lind, a Scottish surgeon with the British Royal
In 1927, Austrian physician Julius Wagner-Jauregg won the Nobel Prize in Physiology or Medicine for his discovery of the therapeutic value of malaria inoculation in
Injecting cancerous tumors with microscopic particles and then zapping them with lasers seems like an idea ripped straight from the pages of science fiction. Yet,
Increasingly, cancer researchers are discovering novel biological pathways that regulate the expression of various genes that are often strongly associated with tumorigenesis. These new molecular
The device: A patch containing 121 microneedles loaded with specialized nanoparticles designed to release insulin when glucose levels are high could make insulin delivery a
Results of a small clinical trial support the feasibility of using a multiple myeloma patient’s marrow-infiltrating lymphocytes (MILs) as the basis for adoptive T cell
Results of a small clinical trial support the feasibility of using a multiple myeloma patient’s marrow-infiltrating lymphocytes (MILs) as the basis for adoptive T cell
By now, it has become readily apparent to most that protracted exposure to the sun and UV rays leads to increased incidences of skin cancer,
A collaboration of scientists from across Europe has discovered a cellular pathway that could lead to the development of new therapeutic interventions to stop or
A growing body of research suggests that the most common cause of dementia in older people is a mix of vascular and Alzheimer’s-related brain abnormalities,
A growing body of research suggests that the most common cause of dementia in older people is a mix of vascular and Alzheimer’s-related brain abnormalities,
Although some people spend countless dollars on antioxidant supplements to improve their health, many studies have found that these would-be panaceas could actually exacerbate the
In the quest to develop personalized cancer therapies, researchers are increasingly examining an individual’s immune response to cancer to find ways to tailor treatments. The
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers in western countries, with a median survival of 6 months and an extremely low percentage
Statins may aid in bone growth in people with dwarfism caused by mutations in the gene FGFR3, according to a study published today (September 17) in Nature.
A Japanese woman in her 70s is the world’s first recipient of cells derived from induced pluripotent stem cells, a technology that has created great
Whole-genome sequences from 128 healthy Jewish people could help the medical community identify disease-associated variants in those of Ashkenazi ancestry, according to a study published
Merck & Co. has won FDA approval for its melanoma immunotherapy Keytruda (pembrolizumab), formerly called MK-3475—the first programmed death receptor-1 (PD-1) inhibitor to be allowed for use as a
Merck & Co. has won FDA approval for its melanoma immunotherapy Keytruda (pembrolizumab), formerly called MK-3475—the first programmed death receptor-1 (PD-1) inhibitor to be allowed for use as a
The hypoxic conditions within tumours are implicated in resistance to therapy, but might provide the ideal environment for the growth of anaerobic bacteria capable of
Created by ePubSystems. Contact Us for similar site for your university or institute.